Cited by 665Prostate Cancer Diagnosis and TreatmentProstate Cancer Treatment and ResearchBreast Cancer Treatment Studies

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.

Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer

Open access

Shipley, William U., Seiferheld, Wendy, Lukka, Himanshu R., Major, Pierre P., Heney, Niall M., Grignon, David J., Sartor, Oliver, Patel, Maltibehn P., Bahary, Jean-Paul, Zietman, Anthony L., Pisansky, Thomas M., Zeitzer, Kenneth L., Lawton, Colleen A.F., Feng, Felix Y., Lovett, Richard D., Balogh, Alexander G., Souhami, Luis, Rosenthal, Seth A., Kerlin, Kevin J., Dignam, James J., Pugh, Stephanie L., Sandler, Howard M.·2017·New England Journal of Medicine

DOI 10.1056/nejmoa1607529PMC PMC5444881

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Salvage radiation therapy is often necessary in men who have undergone radical prostatectomy and have evidence of prostate-cancer recurrence signaled by a persistently or recurrently elevated prostate-specific antigen (PSA) level. Whether antiandrogen therapy with radiation therapy will further improve cancer control and prolong overall survival is unknown. METHODS: In a double-blind, placebo-controlled trial conducted from 1998 through 2003, we assigned 760 eligible patients who had undergone prostatectomy with a lymphadenectomy and had disease, as assessed on pathological testing, with a tumor stage of T2 (confined to the prostate but with a positive surgical margin) or T3 (with histologic extension beyond the prostatic capsule), no nodal involvement, and a detectable PSA level of 0.2 to 4.0 ng per milliliter to undergo radiation therapy and receive either antiandrogen therapy (24 months of bicalutamide at a dose of 150 mg daily) or daily placebo tablets during and after radiation therapy. The primary end point was the rate of overall survival. RESULTS: The median follow-up among the surviving patients was 13 years. The actuarial rate of overall survival at 12 years was 76.3% in the bicalutamide group, as compared with 71.3% in the placebo group (hazard ratio for death, 0.77; 95% confidence interval, 0.59 to 0.99; P=0.04). The 12-year incidence of death from prostate cancer, as assessed by means of central review, was 5.8% in the bicalutamide group, as compared with 13.4% in the placebo group (P<0.001). The cumulative incidence of metastatic prostate cancer at 12 years was 14.5% in the bicalutamide group, as compared with 23.0% in the placebo group (P=0.005). The incidence of late adverse events associated with radiation therapy was similar in the two groups. Gynecomastia was recorded in 69.7% of the patients in the bicalutamide group, as compared with 10.9% of those in the placebo group (P<0.001). CONCLUSIONS: The addition of 24 months of antiandrogen therapy with daily bicalutamide to salvage radiation therapy resulted in significantly higher rates of long-term overall survival and lower incidences of metastatic prostate cancer and death from prostate cancer than radiation therapy plus placebo. (Funded by the National Cancer Institute and AstraZeneca; RTOG 9601 ClinicalTrials.gov number, NCT00002874 .).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa1607529

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Evaluation of survival data and two new rank order statistics arising in its consideration.
Mantel, N. (1966) · PubMed · Cited by 7,516
A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk
Gray, R. J. (1988) · The Annals of Statistics · doi:10.1214/aos/1176350951 · Cited by 4,957
Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European organization for research and treatment of cancer (EORTC)
Cox, J. D., Stetz, J., & Pajak, T. F. (1995) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(95)00060-c · Cited by 4,811
Radical Prostatectomy versus Observation for Localized Prostate Cancer
Wilt, T. J., Brawer, M. K., Jones, K. M., Barry, M. J., Aronson, W. J., Fox, S., Gingrich, J. R., Wei, J. T., Gilhooly, P. E., Grob, B. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113162 · Cited by 1,767
An Assessment of Clinically Useful Measures of the Consequences of Treatment
Laupacis, A., Sackett, D. L., & Roberts, R. S. (1988) · New England Journal of Medicine · doi:10.1056/nejm198806303182605 · Cited by 1,681
Improved Survival in Patients with Locally Advanced Prostate Cancer Treated with Radiotherapy and Goserelin
Bolla, M., González, D., Warde, P. R., Dubois, J. B., Mirimanoff, R., Storme, G. A., Bernier, J., Kuten, A., Sternberg, C. N., Gil, T., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199707313370502 · Cited by 1,547
Predicting the Outcome of Salvage Radiation Therapy for Recurrent Prostate Cancer After Radical Prostatectomy
Stephenson, A. J., Scardino, P. T., Kattan, M. W., Pisansky, T. M., Slawin, K. M., Klein, E. A., Anscher, M. S., Michalski, J. M., Sandler, H. M., Lin, D. W., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.9607 · Cited by 889
Self-citation
Calculating the number needed to treat for trials where the outcome is time to an event
Altman, D. G., & Andersen, P. K. (1999) · BMJ · doi:10.1136/bmj.319.7223.1492 · Cited by 710

Flagged first, then by citations

Show all 29 references

Research works printed but not linked: 3

American Joint Commission on Cancer. AJCC cancer staging manual. 5th ed. Philadelphia: Lippincott-Raven, 1997.
10.2307/2281868 · DOI · Paper page
Mantel N, 1966, Cancer Chemother Rep, 50, 163

Sorted by citations

Items 501–600 of 665

Salvage Treatment After Radical Prostatectomy
Parker, C. C., & Sydes, M. R. (2017) · European Urology · doi:10.1016/j.eururo.2017.07.025 · Cited by 1
“They rightly focus more on the RTOG 9601 trial [4] because the longer follow-up provides more data on clinically meaningful longterm outcomes.”
BackgroundInfluential
Re: Giorgio Gandaglia, Stephen A. Boorjian, William P. Parker, et al. Impact of Postoperative Radiotherapy in Men with Persistently Elevated Prostate-specific Antigen After Radical Prostatectomy for Prostate Cancer: A Long-term Survival Analysis. Eur Urol 2017;72:910–7
Pra, A. D., Supiot, S., & Ghadjar, P. (2017) · European Urology · doi:10.1016/j.eururo.2017.08.025 · Cited by 1
Who benefits most from early salvage radiation therapy after prostatectomy?
Nath, S. K., Rose, B. S., & Pugh, T. J. (2018) · Translational Andrology and Urology · doi:10.21037/tau.2017.11.23 · Cited by 1
“Furthermore, recent data supports a survival benefit of the addition of ADT with SRT (14).”
Background
Optimal Treatment for High-Risk Prostate Cancer—Reply
Kishan, A. U., Cook, R., & King, C. R. (2018) · JAMA · doi:10.1001/jama.2018.6721 · Cited by 1
Re: Amar U. Kishan, Rahul D. Tendulkar, Phuoc T. Tran, et al. Optimizing the Timing of Salvage Postprostatectomy Radiotherapy and the Use of Concurrent Hormonal Therapy for Prostate Adenocarcinoma. Eur Urol Oncol. In press
Spratt, D. E., & Feng, F. Y.-C. (2018) · European Urology Oncology · doi:10.1016/j.euo.2018.06.016 · Cited by 1
Self-citation
Treatment Modalities in Prostate Cancer
Evren, İ., & Tuğcu, V. (2018) · Nuclear Medicine Seminars · doi:10.4274/nts.2018.022 · Cited by 1
Bestrahlung mit zusätzlicher Antiandrogentherapie beim Prostatakarzinomrezidiv
Roth, S. L. (2017) · Strahlentherapie und Onkologie · doi:10.1007/s00066-017-1171-4 · Cited by 1
“Ein biochemisches Rezidiv in der RTOG-Studie trat innerhalb von 12 Jahren in 44% in der Bicalutamidgruppe auf im Vergleich zu 67,9% in der Placebogruppe (HR 0,48; p < 0,001).”
BackgroundInfluential
Androgen deprivation therapy plus salvage radiotherapy after prostatectomy
Birer, S. R., & Spratt, D. E. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30805-8 · Cited by 1
Salvage Treatment for Biochemical Failure After Radical Prostatectomy: Do We Now Have the Answers?
Kneebone, A. B., & Bergamin, S. (2020) · European Urology · doi:10.1016/j.eururo.2020.01.028 · Cited by 1
Reply to Wei Liu, Katherine Zukotynski, and Glenn Bauman’s Letter to the Editor re: Rachel M. Glicksman, Ur Metser, Douglass Vines, et al. Curative-intent Metastasis-directed Therapies for Molecularly-defined Oligorecurrent Prostate Cancer: A Prospective Phase II Trial Testing the Oligometastasis Hypothesis. Eur Urol 2021;80:374–82
Glicksman, R., & Berlín, A. (2021) · European Urology · doi:10.1016/j.eururo.2021.06.004 · Cited by 1
Prostate Cancer
Thorpe, C. S., Bhangoo, R. S., Anderson, J. D., Shen, J., & Vargas, C. (2022) · doi:10.1002/9781119707530.ch21 · Cited by 1
Further Randomized Data Confirming Minimal Benefit from the Addition of Hormone Therapy to Postoperative Radiotherapy
Spratt, D. E. (2024) · European Urology · doi:10.1016/j.eururo.2024.08.024 · Cited by 1
Re: Duration of Androgen Deprivation Therapy with Postoperative Radiotherapy for Prostate Cancer: A Comparison of Long-course Versus Short-course Androgen Deprivation Therapy in the RADICALS-HD Randomised Trial
Ghadjar, P., & Zips, D. (2024) · European Urology · doi:10.1016/j.eururo.2024.10.028 · Cited by 1
Improved Therapy for PSA Recurrence after Prostatectomy
Thompson, I. M. (2017) · New England Journal of Medicine · doi:10.1056/nejme1614133
Prostatakrebs: Strahlentherapie plus Antihormontherapie bei PSA-Rückfall
Rukavina, M. (2017) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/s-0043-104116
Antiandrogen tilleggsbehandling ved residiv av prostatakreft
Tveito, K. (2017) · Tidsskrift for Den norske legeforening · doi:10.4045/tidsskr.17.0186
Salvage-Radiotherapie mit oder ohne Kurzzeit-Antihormonbehandlung
Hermann, R. M., & Christiansen, H. (2017) · Info Onkologie · doi:10.1007/s15004-017-5655-2
Prostatakarzinom: Antiandrogen verbessert Ergebnis der Salvage-Bestrahlung
Leiner, P. (2017) · Uro-News · doi:10.1007/s00092-017-1485-7
Salvage-Radiotherapie mit antiandrogener Therapie nach Prostatektomie
Goldner, G. M. (2017) · Strahlentherapie und Onkologie · doi:10.1007/s00066-017-1148-3
Post-prostatectomy Radiotherapy: Does “Salvage” Really Equal “Adjuvant”?
Bossi, A., & Cozzarini, C. (2017) · European Urology · doi:10.1016/j.eururo.2017.06.003
Re: Radiation with or Without Antiandrogen Therapy in Recurrent Prostate Cancer
D’Andrea, D., & Shariat, S. F. (2017) · European Urology · doi:10.1016/j.eururo.2017.06.018
Improving postoperative radiotherapy following radical prostatectomy
Lipman, D., Pieters, B. R., & de Reijke, T. M. (2017) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2017.1364994
“5 ng/ml and those with PSM in the bicalutamide group compared to the salvage radiotherapy group [80].”
Result
Addition der antiandrogenen Therapie, eine Option
Goldner, G. M. (2017) · Info Onkologie · doi:10.1007/s15004-017-5811-8
Pharmacodynamic Evaluation: Endocrinology
Naafs, M. A. (2017) · Springer eBooks · doi:10.1007/978-3-319-56637-5_35-1
Re: Daniel E. Spratt, Robert T. Dess, Zachary S. Zumsteg, et al. A Systematic Review and Framework for the Use of Hormone Therapy with Salvage Radiation Therapy for Recurrent Prostate Cancer. Eur Urol 2018;73:156–65
Ghadjar, P., & Wiegel, T. (2017) · European Urology · doi:10.1016/j.eururo.2017.10.005
“The RTOG 9601 trial [2] recruited its 760 patients between 1998 and 2003.”
Method
Zusätzliche Androgenblockade verlängert Überleben bei rezidiviertem Prostatakarzinom
Kreutzkamp, B., & Schneider, T. (2017) · Im Focus Onkologie · doi:10.1007/s15015-017-3626-y
Editorial: Controversies and Perspectives in the Use of Postoperative Radiotherapy for Prostate Cancer
Pra, A. D., Zilli, T., & Supiot, S. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00275
“Recently, two prospective phase III trials (RTOG 9601 and GETUG-16) have shown improvements in disease outcomes when ADT is combined with salvage radiotherapy (3, 4).”
Background
Reply to Mustafa Z. Temiz and Huseyin Besiroglu's Letter to the Editor re: Giorgio Gandaglia, Stephen A. Boorjian, William P. Parker, et al. Impact of Postoperative Radiotherapy in Men with Persistently Elevated Prostate-specific Antigen After Radical Prostatectomy for Prostate Cancer: A Long-term Survival Analysis. Eur Urol 2017;72:910–7
Gandaglia, G., Fossati, N., Montorsi, F., & Briganti, A. (2018) · European Urology · doi:10.1016/j.eururo.2018.01.015
Bestrahlung mit zusätzlicher Antiandrogentherapie
Roth, S. L. (2018) · Info Onkologie · doi:10.1007/s15004-018-6049-9
Adjuvant Radiation Therapy for High-Risk Post-prostatectomy Patients
Jackson, W., Spratt, D. E., & Morgan, T. M. (2018) · Springer eBooks · doi:10.1007/978-3-319-78646-9_7
Generating a Hypothesis for an Oncology Study
Costa, B. T., Ferreira, I. S., & Fregni, F. (2018) · Springer eBooks · doi:10.1007/978-3-319-71324-3_2
Avances en radio oncología de tumores urologicos
Besa, P. (2018) · Revista Médica Clínica Las Condes · doi:10.1016/j.rmclc.2018.01.005
Vroege oncologische uitkomsten van [68Ga]PSMA-PET/CT-gestuurde salvagetherapie bij mannen met biochemisch recidief na radicale prostatectomie
van Leeuwen, P. J., Emmett, L., Donswijk, M. L., Stricker, P. D., Pos, F. J., Wit, E. M. K., & van der Poel, H. G. (2018) · Tijdschrift voor Urologie · doi:10.1007/s13629-018-00215-w
Lower urinary tract infections from external beam radiation therapy in prostate cancer: A single institution experience
Roviello, G., Generali, D., Aieta, M., & Bonetta, A. (2018) · Reports of Practical Oncology & Radiotherapy · doi:10.1016/j.rpor.2018.06.001
Optimal Treatment for High-Risk Prostate Cancer
Ong, W. L., Koh, T. L., & Millar, J. L. (2018) · JAMA · doi:10.1001/jama.2018.6709
RADICAL(S) Radiotherapy Post-prostatectomy, Current and Future Practice
McGrane, J., Mark, F., Troup, J., Parker, C. C., & Payne, H. A. (2018) · Clinical Oncology · doi:10.1016/j.clon.2018.08.014
Récidive biologique après prostatectomie totale dans le cancer de la prostate : quel bilan et quel traitement en 2019 ?
Lesourd, M., Roumiguié, M., & Beauval, J. (2018) · Progrès en Urologie - FMC · doi:10.1016/j.fpurol.2018.08.002
“Récemment, le RTOG 9601 a montré que l'adjonction du bicalutamide (24 mois) à la RT de rattrapage apportait un béné ﬁ ce en survie spéci ﬁ que et survie globale [12].”
Background
Androgen deprivation therapy use with post‐prostatectomy radiotherapy in the Prostate Cancer Outcomes Registry Victoria
Ong, W. L., Foroudi, F., Evans, S., & Millar, J. L. (2018) · Journal of Medical Imaging and Radiation Oncology · doi:10.1111/1754-9485.12818
Rolle der kombinierten ADT und SRT nach radikaler Prostatektomie im primären Stadium pN0
Bottke, D., Böhmer, D., Höcht, S., Schmidt-Hegemann, N.-S., Ott, S., Ganswindt, U., Bolenz, C., & Wiegel, T. (2019) · Der Onkologe · doi:10.1007/s00761-019-0530-4
Androgen Deprivation Therapy with Postprostatectomy Radiotherapy: For Whom and for How Long?
Dearman, C., & Parker, C. C. (2019) · European Urology · doi:10.1016/j.eururo.2019.03.004
Management of Nonmetastatic Failure Following Local Prostate Cancer Therapy
Ambuehl, D., Boxler, S., Thalmann, G. N., & Spahn, M. (2019) · Springer eBooks · doi:10.1007/978-3-319-42623-5_75
Salvage radiation therapy following radical prostatectomy in Stockholm County in 2008–2016
Falk, J., Aly, M., Berglund, A., Nordström, T., & Valdman, A. (2019) · Journal of Radiation Oncology · doi:10.1007/s13566-019-00393-z
Dosimetric and clinical factors predicting quality of life after post prostatectomy radiation therapy: useful tool or not?
Carrié, C., & Bringeon, G. (2019) · Translational Andrology and Urology · doi:10.21037/tau.2019.08.04
Sodium salicylate effects on prostate cancer aggressiveness and development of prostate cancer spheroids for drug evaluation
Wang, R. (2019) · Cronfa (Swansea University) · doi:10.23889/suthesis.51919
Androgen deprivation therapy plus salvage radiotherapy after prostatectomy – Authors' reply
Carrié, C., & Chabaud, S. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30813-7
Phase II open-label study investigating apalutamide in patients with biochemical progression after radical prostatectomy
Dirix, P. R., Strijbos, M. H., den Mooter, T. V., Liefhooghe, N., Bruwaene, S. V., Uvin, P., Ghysel, C., Ost, D., Schatteman, P., Bral, S., et al. (2020) · Future Oncology · doi:10.2217/fon-2020-0056
Using hormone therapy with salvage radiotherapy according to presalvage PSA levels
Pra, A. D., & Pollack, A. S. (2020) · Nature Reviews Urology · doi:10.1038/s41585-020-0333-9
Utilization of multimodality therapy with primary radical prostatectomy versus radiation therapy for Gleason 8–10 prostate cancer
King, M. T., Muralidhar, V., Yang, D. D., Mouw, K. W., Martin, N. E., D'Amico, A. V., Nguyen, P. L., & Orio, P. F. (2020) · Brachytherapy · doi:10.1016/j.brachy.2020.09.005
Simplified Predictive Nomogram for Postprostatectomy Patients Treated with High-dose Salvage Intensity Modulated Radiation TherapyPreprint
Wang, Y.-J., Huang, C., Hou, W., Yu, H., Lai, M., Liu, S.-P., Pu, Y., & Cheng, J. C. (2020) · doi:10.21203/rs.3.rs-136186/v1
Postoperative Radiotherapy for Prostate Cancer
Dinh, T.-K. T., Macomber, M. W., & Митин, Т. (2021) · Practical guides in radiation oncology · doi:10.1007/978-3-030-65137-4_9
The Management of Prostate Cancer
Dess, R. T., Jackson, W., & Spratt, D. E. (2021) · Practical guides in radiation oncology · doi:10.1007/978-3-030-65137-4_1
Re: Gaëtan Devos, Gert De Meerleer, Steven Joniau. Have We Entered the Era of Imaging Before Salvage Treatment for Recurrent Prostate Cancer? Eur Urol 2019;76:265–7
Dirix, P. R., Pra, A. D., & Wiegel, T. (2019) · European Urology · doi:10.1016/j.eururo.2019.06.034
Re: Lower Urinary Tract Symptoms and Incident Falls in Community Dwelling Older Men: The Concord Health and Ageing in Men Project
Thomas, D. D. M., & Chughtai, B. I. (2017) · European Urology · doi:10.1016/j.eururo.2017.05.008
Kavita Patel: drug pricing, care access priorities in federal health care policy
McNulty, R. (2021) · The American Journal of Managed Care · doi:10.37765/ajmc.2021.88651
Path to better payment system to be clear over time
Alvarnas, J. (2021) · The American Journal of Managed Care · doi:10.37765/ajmc.2021.88650
Identifying small-cell lung cancer subtypes and potential therapeutic targets
McNulty, R. (2021) · The American Journal of Managed Care · doi:10.37765/ajmc.2021.88652
Genomic cancer profiling: setting a new standard in lung cancer treatment
Dietrich, M. (2021) · The American Journal of Managed Care · doi:10.37765/ajmc.2021.88654
Active treatment of prostate cancer
Hackman, G. (2021) · Työväentutkimus Vuosikirja
Adenocarcinoma of the Prostate: Future Directions for Translational Science
Wang, T., Lewis, B. C., Elaimy, A. L., Ruscetti, M. A., Sokoloff, M. H., Mittal, K., & FitzGerald, T. J. (2021) · Exon Publications eBooks · doi:10.36255/exonpublications.prostatecancer.translationalscience.2021
“Coupled with modern imaging and improvements in image tracers for PET including therapeutic application of radio pharmacy, radiation therapy may evolve into the initial sole modality of care with hormone and hormone-associated analog therapy moved to second line management, even for hormone-sensitive disease (5).”
Background
Radiothérapie postopératoire des cancers de la prostate : à quel moment la proposer ? Quelle place pour la déprivation androgènique ?
Benziane-Ouaritini, N., Sargos, P., Beauval, J., Supiot, S., & Latorzeff, I. (2021) · Cancer/Radiothérapie · doi:10.1016/j.canrad.2021.07.005
Salvage Local Treatment for Localized Radio-Recurrent Prostate Cancer: A Narrative Review and Future Perspectives
Büchser, D., López, R. A. M., Mayrata, E., González, A., Marbán, M., Achard, V., Alongi, F., Iturriaga, A. G., & Couñago, F. (2021) · Future Oncology · doi:10.2217/fon-2021-0320
Radio-hormonothérapie des cancers de la prostate : quelle efficacité ? Quels mécanismes ?
Ah-Thiane, L., Guimas, V., Rio, E., Vaugier, L., Masson, I., Libois, V., & Supiot, S. (2021) · Progrès en Urologie - FMC · doi:10.1016/j.fpurol.2021.09.002
Radiotherapie beim Prostatakarzinom – kurativ und palliativ
Papachristofilou, A., & Zimmermann, F. B. (2021) · Urologie in der Praxis · doi:10.1007/s41973-021-00162-x
Crítica literaria d'abans i d'avui
Vilaplana, A. (1999) · Serra d'Or
Prostate Cancer
Garcia, M. A., Hansen, E. K., & Roach, M. (2018) · Springer eBooks · doi:10.1007/978-3-319-62642-0_26
Prostate Cancer
Solanki, A. A., Hartman, R. I., Gray, P. J., Rose, B. S., Paly, J. J., Mouw, K. W., & Efstathiou, J. A. (2017) · doi:10.1002/9781119341154.ch27
Literatur zu Giordano/Wenz: Strahlentherapie kompakt, 3. Auflage
(2019) · Elsevier eBooks · doi:10.1016/b978-3-437-23292-3.00038-6
Prostate Cancer
Liaw, B. C.-H., & Oh, W. K. (2018) · Wiley eBooks · doi:10.1002/9781118592168.ch26 · Cited by 1
Prostatakarzinom
(2018) · Elsevier eBooks · doi:10.1016/b978-3-437-21161-4.00007-9
Current Imaging in Metastatic Bone Diseases: Does PET Replace Bone Scintigraphy
Özülker, F., & Özülker, T. (2022) · Nuclear Medicine Seminars · doi:10.4274/nts.galenos.2022.0010
High-Risk Localized Prostate Cancer
Cole, A. P., Trinh, Q., & Kibel, A. S. (2022) · Springer eBooks · doi:10.1007/978-3-030-89891-5_4
Pharmacodynamic Evaluation: Endocrinology
Naafs, M. A. (2020) · Springer eBooks · doi:10.1007/978-3-319-68864-0_35
The Indication of Antiandrogen Therapy and Timing of Radiotherapy in Case of Prostate Cancer Relapse – a Literature Discussion on Shipley et al. 2017
(2018) · International Journal of Cancer Research & Therapy · doi:10.33140/ijcrt/03/01/00003
Prostatakarzinom
Wenz, F. K. (2019) · Elsevier eBooks · doi:10.1016/b978-3-437-23292-3.00015-5
Management of Nonmetastatic Failure Following Local Prostate Cancer Therapy
Ambuehl, D., Boxler, S., Thalmann, G. N., & Spahn, M. (2018) · Springer eBooks · doi:10.1007/978-3-319-42603-7_75-1
Salvage Radiotherapy
Perna, C., Uribe, J., Uribe‐Lewis, S., & Langley, S. E. M. (2020) · Springer eBooks · doi:10.1007/978-3-030-57181-8_10
In Regard to Jia et al
Tree, A. C., Griffin, C. L., Hall, E., & Dearnaley, D. P. (2022) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2022.02.013
Prostate Cancer
De, S. K. (2022) · Wiley eBooks · doi:10.1002/9783527838561.ch16
PROshot: Prone Positioning, Radiation First in Total Neoadjuvant Therapy, Palliative Craniospinal Irradiation, Long-Term Androgen Deprivation Therapy, and Combining Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Coverage With Salvage Prostate Radiation
Dulaney, C. R., & Dover, L. L. (2022) · Practical Radiation Oncology · doi:10.1016/j.prro.2022.06.011
Neoplasms of the Prostate
Aparicio, A. M., Pilie, P. G., Surasi, D. S., Choi, S., Chapin, B. F., Logothetis, C. J., & Corn, P. G. (2022) · Wiley eBooks · doi:10.1002/9781119000822.hfcm099.pub2
Moderately hypofractionated salvage radiotherapy in patients with biochemical recurrence of prostate cancer after prostatectomy: long-term results and comparative analysis of two schedules
Matrone, F., Donofrio, A., Fanetti, G., Revelant, A., Polesel, J., Chiovati, P., & Bortolus, R. (2022) · Neoplasma · doi:10.4149/neo_2022_220825n864
PROshot: Borderline Resectable Pancreas SBRT, Surrogate Endpoints, Axillary Dissection, Genomic Classifiers, and Spine SBRT
Dover, L. L., & Dulaney, C. R. (2022) · Practical Radiation Oncology · doi:10.1016/j.prro.2022.09.001
Radiotherapy after radical prostatectomy
Milecki, P., & Trzcińska, S. (2022) · Letters in Oncology Science · doi:10.21641/los.2022.19.1.216
Minimal Residual Disease (MRD) and a New Immunotherapy in Locally Advanced Prostate Cancer
Nicolini, A., & Ferrari, P. (2022) · Interdisciplinary cancer research · doi:10.1007/16833_2022_30
Utilizing clinical, pathological and radiological information to guide postoperative radiotherapy in prostate cancer
Padayachee, J., Chaudhary, S., Shim, B. H., So, J., Lim, R., & Raman, S. (2023) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2023.2181795
“The RTOG 9601 trial reported by Shipley et al, evaluated the use of 2 years Bicalutamide versus placebo in 760 patients planned for sPBRT [64].”
Method
Adverse risk factors for salvage radiotherapy outcomes after radical prostatectomy in prostate cancer patients
Yıldırım, H. C., Dinçer, S. T., Yaprak, G., Kaydıhan, N., Barlas, C., Çakıroğlu, N., Varan, M. P., Can, G., & Dinçbaş, F. Ö. (2023) · World Journal of Urology · doi:10.1007/s00345-023-04419-7
Salvage prostate bed plus elective pelvic node radiation without androgen deprivation therapy
Swanson, G. P., Hammonds, K. A. P., & Jhavar, S. G. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-05085-3
“Randomized trials have also demonstrated superior efficacy of PBRT plus androgen deprivation therapy (ADT) versus PBRT alone (Shipley et al. 2017; Carrie et al. 2019) and superior efficacy of PBRT plus ADT plus elective pelvic nodal radiation (EPNI) versus PBRT alone or PBRT plus ADT in the salvage…”
BackgroundMethodInfluential
Salvage Versus Adjuvant Radiation Therapy Following Radical Prostatectomy in Localised Prostate Cancer: A War Without a Winner
Rodríguez‐Sánchez, L., Macek, P., Lanz, C., Mandoorah, Q., Dias, N., Colandrea, G., Secin, F. P., Arora, A. M., Sánchez-Salas, R., & Cathelineau, X. (2023) · Société Internationale d’Urologie Journal · doi:10.48083/msvk1934
Adjuvant Treatment and Follow Up after Radical Prostatectomy in Prostate Cancer
Haresh, K. P., & Anjali, V. R. (2023) · Springer eBooks · doi:10.1007/978-981-99-2341-0_18
Salvage Radiotherapy for Relapsed Prostate Cancer after Radical Prostatectomy Is Associated with Normal Life Expectancy
Lohm, G., Knörnschild, F., Neumann, K., Budach, V., Schwartz, S., Burock, S., & Böhmer, D. (2024) · Cancers · doi:10.3390/cancers16030534
Urologische Tumoren
Mohnike, W., Magheli, A., Lampe, M., Fink, C. A., Schmitt, D. R., Niegisch, G., & Körber, S. A. (2024) · Springer eBooks · doi:10.1007/978-3-662-67192-4_10
Evaluating appropriateness of 18F-fluciclovine PET/CT relative to standard of care imaging guidelines and the impact of ADT on positivity: a prospective study in 62 Veterans Administration patients at a single institution
Green, A., Temsah, P., Goldfarb, L., Sanfolippo, K., Knoche, E. M., Muzaffar, R., & Osman, M. (2024) · Nuclear Medicine Communications · doi:10.1097/mnm.0000000000001836
“Furthermore, prostate cancer biochemical recurrence (BCR) after curative intent treat-ment affects 30 – 50% of patients in the first 10 years after initial therapy [4,5].”
Background
Additional file 3 of Characterization of metabolism-associated molecular patterns in prostate cancer
Yang, B., Jiang, Y., Yang, J., Zhou, W., Yang, T., Zhang, R., Xu, J., & Guo, H. (2023) · Figshare · doi:10.6084/m9.figshare.23304958
Additional file 4 of Characterization of metabolism-associated molecular patterns in prostate cancer
Yang, B., Jiang, Y., Yang, J., Zhou, W., Yang, T., Zhang, R., Xu, J., & Guo, H. (2023) · Figshare · doi:10.6084/m9.figshare.23304961
Additional file 1 of Characterization of metabolism-associated molecular patterns in prostate cancer
Yang, B., Jiang, Y., Yang, J., Zhou, W., Yang, T., Zhang, R., Xu, J., & Guo, H. (2023) · Figshare · doi:10.6084/m9.figshare.23304952
European association of urology biochemical recurrence risk stratification in the context of post-prostatectomy salvage therapy
Lin, T. A., & Song, D. Y. (2024) · Translational Andrology and Urology · doi:10.21037/tau-23-603
Adjuvant versus salvage radiotherapy: debates will be reignited
Spratt, D. E. (2024) · Annals of Oncology · doi:10.1016/j.annonc.2024.04.011
Helpful tool or blunt instrument?—the European Association of Urology Biochemical Recurrence Risk Classification as a decision-making tool for salvage radiotherapy
Correa, R. J. M., & Mendez, L. C. (2024) · Translational Andrology and Urology · doi:10.21037/tau-23-665
Controversies in Management of Localized Prostate Cancer: Before and After Radical Local Therapy
Ghosh, J., & Ghose, A. (2024) · UroCancer Clinics of India . · doi:10.4103/ucci.ucci_7_24
Analysis of risk factors for disease progression after salvage radiation therapy with androgen deprivation therapy in prostate cancer patients who have prostate-specific antigen persistence after radical prostatectomy
Lee, K., Kim, D., Nam, J., Park, D., Kim, W., Joo, J. H., Jeon, H., Ki, Y., & Kim, D. H. (2024) · Radiation Oncology Journal · doi:10.3857/roj.2023.00962

Authors: Shipley, W. U., Seiferheld, W., Lukka, H. R., Major, P. P., Heney, N. M., Grignon, D. J., Sartor, O., Patel, M. P., Bahary, J.-P., Zietman, A. L., Pisansky, T. M., Zeitzer, K. L., Lawton, C. A. F., Feng, F. Y., Lovett, R. D., Balogh, A. G., Souhami, L., Rosenthal, S. A., Kerlin, K. J., Dignam, J. J., Pugh, S. L., & Sandler, H. M.
Affiliations: Cedars-Sinai Medical Center (US)
Tulane University (US)
ORCID: Shipley, William U.
Major, Pierre P.
Grignon, David J.
Sartor, Oliver
Bahary, Jean-Paul
Zietman, Anthony L.
Pisansky, Thomas M.
Zeitzer, Kenneth L.
Feng, Felix Y.
Rosenthal, Seth A.
Dignam, James J.
Pugh, Stephanie L.
Sandler, Howard M.
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2017-02-02
Volume: 376
Issue: 5
Pages: 417-428
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa1607529
PMC: PMC5444881
OpenAlex: W2585109238
Cited by: 663
References: 29
Citations by year: 2026: 32 · 2025: 54 · 2024: 65 · 2023: 50 · 2022: 63 · 2021: 84 · 2020: 81 · 2019: 86 · 2018: 78 · 2017: 68
FWCI: 70.79
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: National Cancer Institute (UG1CA189867, U10CA180868, U10CA180801, U10CA021661, U10CA180822)
Topics: Health Sciences › Medicine › Urology › Prostate Cancer Diagnosis and Treatment
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
Keywords: recurrent prostate cancer, salvage radiotherapy, antiandrogen therapy, bicalutamide, prostate-specific antigen, radical prostatectomy, overall survival, metastatic prostate cancer, gynecomastia, androgen deprivation therapy, lymph node dissection, long-term follow-up
MeSH terms: Aged, Aged, 80 and over, Androgen Antagonists, Anilides, Combined Modality Therapy, Double-Blind Method, Follow-Up Studies, Gynecomastia, Humans, Male, Middle Aged, Neoplasm Metastasis, Neoplasm Recurrence, Local, Neoplasm Staging, Nitriles, Prostatectomy, Prostatic Neoplasms, Radiotherapy, Tosyl Compounds, Incidence, Survival Rate, Kaplan-Meier Estimate

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks